William Farkas
Family Medicine · Honea Path, SCNPI 1366798563
Payments from drug & device makers
Across 471 payments — averaging $15.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$873
- AstraZeneca$747
- Novo Nordisk$600
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$579
- Pfizer$571
- plus $3K from 32 others
What the payments were for
- Food & beverage$7,317100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 91 | $1,221 |
| Lilly USA, LLC | 65 | $873 |
| AstraZeneca | 34 | $747 |
| Novo Nordisk | 42 | $600 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 35 | $579 |
| Pfizer | 39 | $571 |
| GSK | 23 | $345 |
| Novartis | 20 | $310 |
| Amgen | 19 | $302 |
| Otsuka America Pharmaceutical, Inc. | 11 | $211 |
| Boehringer Ingelheim | 13 | $208 |
| Esperion Therapeutics, Inc. | 12 | $197 |
| Abbott | 8 | $129 |
| Sanofi-aventis U.S. LLC | 7 | $119 |
| Exact Sciences | 7 | $112 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $97 |
| Idorsia Pharmaceuticals US Inc | 4 | $65 |
| Edwards Lifesciences | 2 | $63 |
| Lundbeck LLC | 2 | $56 |
| Astellas Pharma US Inc | 3 | $56 |
| Merck | 4 | $53 |
| Daiichi Sankyo Inc. | 2 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $42 |
| Sunovion Pharmaceuticals Inc. | 3 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $37 |
| Axsome Therapeutics, Inc. | 2 | $36 |
| Phathom Pharmaceuticals, Inc. | 2 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Dexcom, Inc. | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Dynavax Technologies Corporation | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Medtronic | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $11 |
| Organon | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,331 in reported general payments places this provider in the 90th percentile of 2,153 family medicine providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 59 | $69,821 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 91 | $64,055 |
| UbrelvyUbrogepant | 39 | $47,775 |
| EliquisApixaban | 41 | $44,056 |
| MounjaroTirzepatide | 38 | $40,283 |
| LinzessLinaclotide | 36 | $32,611 |
| JardianceEmpagliflozin | 29 | $31,315 |
| FarxigaDapagliflozin Propanediol | 20 | $23,453 |
| JanuviaSitagliptin Phosphate | 26 | $19,937 |
| VraylarCariprazine Hcl | 14 | $19,231 |
| TrulicityDulaglutide | 16 | $15,380 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 651 | $15,114 |
| TrintellixVortioxetine Hydrobromide | 24 | $12,392 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $9,860 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $9,141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Linzess, Vraylar | $1,221 | $99,61789 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $345 | $70,905106 claims |
| Novo NordiskOzempic | $600 | $69,82159 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $873 | $61,29169 claims |
| PfizerEliquis, Premarin | $571 | $46,90754 claims |
| Boehringer IngelheimJardiance | $208 | $31,31529 claims |
| AstraZenecaFarxiga, Symbicort | $747 | $27,97736 claims |
| MerckJanuvia | $53 | $19,93726 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $37 | $12,39224 claims |
| Astellas Pharma US IncMyrbetriq | $56 | $8,32711 claims |
| Sanofi-aventis U.S. LLCLantus | $119 | $2,08515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Honea Path
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
- Edward NewtonCharleston$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.